

**Table 2.** Coagulation defects in women with untreated thrombophilia (Untreated Thrombophilia group), and women with thrombophilia treated with Enoxaparin (Treated Thrombophilia group). Groups were compared with a Chi-square test. Differences were considered significant at the 5 % threshold.

	Untreated Thrombophilia (n=30)	Treated Thrombophilia (n=54)	p (Chi-square)
Factor V Leiden (% altered)	0 %	1.9 %	0.453
Methylenetetrahydrofolate Reductase (% altered)	86.2 %	86.8 %	0.941
Homocysteine (% altered)	10.7 %	9.8 %	0.898
Anticardiolipin antibodies (% altered)	18.5 %	30.8 %	0.242
Antiphospholipid antibodies (% altered)	17.2 %	9.4 %	0.302
Lupus anticoagulant (% altered)	3.3 %	1.9 %	0.670
Antiphosphatidylserine antibodies (% altered)	21.4 %	57.4 %	0.002 *
Protein S (% altered)	3.6 %	13.5 %	0.160
Protein C (% altered)	10.7 %	1.9 %	0.085
Antinuclear antibodies (% altered)	10.7 %	9.6 %	0.876

\* - statistically significant difference (p<0.05)